Christina M Coughlin

US Patent:

20030147871, Aug 7, 2003

Filed:

Jan 29, 2003

Appl. No.:

10/353283

Inventors:

Giorgio Trinchieri - Wynnewood PA, US
William Lee - Wynnewood PA, US
Christina Coughlin - Philadelphia PA, US

Assignee:

The Trustees of the University of Pennsylvania - Philadelphia PA

International Classification:

A61K048/00

US Classification:

424/093210

Abstract:

A composition useful for preventing, or retarding the growth of, tumor cells contains synergistic amounts of Interleukin-12 and Interleukin-18. Similarly, methods for treating or preventing cancer include co-administering synergistic amounts of IL-12 and IL-18. The resulting anti-tumor effect is greater than the additive effect of either cytokine administered alone.

US Patent:

20060073159, Apr 6, 2006

Filed:

May 25, 2005

Appl. No.:

11/137253

Inventors:

Robert Vonderheide - Merion Station PA, US
Gregory Beatty - Kennett Square PA, US
Christina Coughlin - Philadelphia PA, US

International Classification:

A61K 39/00
A61K 48/00

US Classification:

424185100, 514044000

Abstract:

The present invention encompasses compositions and methods for activating, stimulating and isolating antigen-specific T cells. The present invention also relates to compositions of antigen-specific T cells and methods of their use in the treatment and prevention of cancer, infectious diseases, autoimmune diseases, immune disfunction related to aging, or any other disease state where antigen-specific T cells are desired for treatment.

US Patent:

20100081666, Apr 1, 2010

Filed:

Jul 14, 2009

Appl. No.:

12/503019

Inventors:

Christina M. COUGHLIN - Berwyn PA, US
Michael E. BURCZYNSKI - Cedar Knolls NJ, US
Marisa P. DOLLED-FILHART - New Haven CT, US
Robert PINARD - Andover MA, US
Donald WALDROM - Fairfield CT, US
Charles ZACHARCHUK - Westford MA, US
Frederick IMMERMANN - Suffern NY, US
Maha KARNOUB - Doylestown PA, US
Jason CHRISTIANSEN - Glastonbury CT, US
Mark GUSTAVSON - Niantic CT, US
Annette MOLINARO - New Haven CT, US
Alpana Waldron - Fairfield CT, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 31/506
C12Q 1/68
C12Q 1/48
C12Q 1/02

US Classification:

51425219, 435 6, 435 15, 435 29, 51425306, 514275

Abstract:

Methods of cancer diagnosis and prognosis using biomarkers.

US Patent:

20120010240, Jan 12, 2012

Filed:

Jan 4, 2011

Appl. No.:

12/984043

Inventors:

Christina Marie Coughlin - Berwyn PA, US
Jay Marshall Feingold - Wynnewood PA, US
Daniel Steven Johnston - Trappe PA, US
Anna Berkenblit - Needham MA, US
Andrew Louis Strahs - Maynard MA, US
Charles Michael Zacharchuk - Westford MA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 31/4709
A61P 35/00
G01N 1/30
C40B 30/04
G01N 33/53

US Classification:

514313, 506 9, 435 74, 435 21

Abstract:

A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.

US Patent:

20130189274, Jul 25, 2013

Filed:

Dec 6, 2010

Appl. No.:

13/514556

Inventors:

Anna Berkenblit - Cambridge MA, US
Christina Marie Coughlin - Berwyn PA, US
Jay Marshall Feingold - Livingston NJ, US
Daniel Stephen Johnston - Collegeville PA, US
Andrew Louis Strahs - Maynard MA, US
Charles Michael Zacharchuk - Cambridge MA, US

International Classification:

A61K 39/395
A61K 45/06
A61K 31/4709

US Classification:

4241451, 435 612, 435 614, 506 9, 514313

Abstract:

Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.

US Patent:

20210060070, Mar 4, 2021

Filed:

Sep 3, 2020

Appl. No.:

17/011636

Inventors:

- Philadelphia PA, US
Christina Coughlin - Philadelphia PA, US

Assignee:

Tmunity Therapeutics Inc. - Philadelphia PA

International Classification:

A61K 35/17
A61K 31/7076
A61K 31/675
A61P 35/00

Abstract:

The present disclosure provides methods for the administration of engineered cells, such as T cells, to subjects for adoptive cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells express chimeric antigen receptors (CARs) and/or T cell receptors (TCRs), and optionally, other molecules to overcome the immunosuppressive tumor microenvironment. Methods provided herein may employ a fractionated dosing regimen which may further comprise monitoring the development of a toxicity and managing the symptoms thereof.

US Patent:

20200040055, Feb 6, 2020

Filed:

Jun 2, 2017

Appl. No.:

16/305838

Inventors:

- Abingdon, Oxfordshire, GB
Christina COUGHLIN - Philadelphia PA, US

Assignee:

Immunocore Limited - Abingdon, Oxfordshire

International Classification:

C07K 14/725
A61P 35/00
C07K 16/28
A61K 39/395
A61K 38/17
A61K 31/4439

Abstract:

The present invention relates to the treatment of cancer, particularly gp100 positive cancers. In particular, it relates to a dosage regimen for a T cell redirecting bispecific therapeutic comprising a targeting moiety that binds the YLEPGPVTA-HLA-A2 complex fused to a CD3 binding T cell redirecting moiety.

US Patent:

20190271047, Sep 5, 2019

Filed:

May 17, 2019

Appl. No.:

16/416083

Inventors:

- New York NY, US
Christina Marie Coughlin - Berwyn PA, US
Jay Marshall Feingold - Wynnewood PA, US
Daniel Stephen Johnston - Trappe PA, US
Andrew Louis Strahs - Maynard MA, US
Charles Michael Zacharchuk - Cambridge MA, US

International Classification:

C12Q 1/6886
C07K 16/30
A61K 31/4709
A61K 39/395
A61K 45/06
C07K 16/28
G01N 33/574

Abstract:

Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.